The principal infectious and pathogenic agent in all prion disorders is a ␤-sheet-rich isoform of the cellular prion protein (PrP  C ) 
INTRODUCTION
Prion disorders result from misfolding of the cellular prion protein (PrP C ) from a ␣-helical to a ␤-sheet-rich PrP-scrapie (PrP Sc ) isoform that is insoluble in nonionic detergents and partially resistant to digestion by proteinase K (PK). Accumulating evidence implicates PrP Sc as the principal infectious and pathogenic agent in familial, infectious, and sporadic prion disorders (Prusiner, 1998; Aguzzi and Polymendiou, 2004) . However, reports suggesting inconsistent correlation between PrP Sc load, neuronal loss, and infectivity implicate other players besides PrP Sc in prion disease-associated neurotoxicity (Lasmezas et al., 1997; Chiesa and Harris, 2001; Harris and True, 2006) . One such player is the expression of PrP C on neuronal plasma membrane. Absence of PrP C renders neurons resistant to toxicity by PrP Sc , whereas down-regulation of neuronal PrP C expression reverses prion pathology in scrapie-infected mice (Mallucci et al., 2003; Chesebro et al., 2005) . Whether PrP C transmits the toxic signal directly or indirectly during conversion to PrP
Sc remains an open question. Recently, markers of oxidative stress and increased ferrous (Fe 2ϩ ) and ferric (Fe 3ϩ ) iron have been reported in the cerebral cortex, striatum, and brain stem of scrapieinfected mice and Creutzfeldt-Jakob disease (CJD)-affected human brains (Kim et al., 2000; Andreoletti et al., 2002; Hur et al., 2002; Fernaeus and Land, 2005) . In some cases, PrP Sc plaques colocalize with redox-active iron, suggesting a strong correlation between oxidative stress, PrP Sc accumulation, and neuronal loss (Petersen et al., 2005) . In addition, peroxidative damage has been linked directly to neuronal loss and de novo PrP Sc propagation in scrapie-infected mice, establishing a causal link between oxidative damage, PrP Sc propagation, and neurotoxicity (Brazier et al., 2006) . Formation of redox-active copper complexes during PrP C -to-PrP Sc conversion (Thackray et al., 2002) and the presence of relatively stable PrP Sc -ferritin complexes in sCJD brain tissue (Mishra et al., 2004) lend further support to the involvement of metal-induced oxidative stress in prion disease pathogenesis. The trigger leading to brain metal imbalance, however, remains unclear. In this report, we provide evidence that PrP C is an iron-binding protein, a characteristic likely to modulate its susceptibility to oxidative damage. Using PrP Cexpressing neuroblastoma cells (PrP C cells), we demonstrate that exposure to a source of redox iron such as inorganic ferrous chloride (FeCl 2 ) induces the conversion of PrP C to a PrP Sc -like form (*PrP Sc ) that resembles brain-derived PrP Sc in several biochemical characteristics, including limited propagation in culture. More significantly, depletion of iron from prion disease-affected human and mouse brains and scrapie-infected mouse neuroblastoma (ScN2a) cells reduces PK-resistant PrP Sc by 4-to 10-fold, suggesting that PrP Sc generation, propagation, and stability are modulated by brain redox iron levels.
EXPERIMENTAL METHODS

Materials
Human neuroblastoma cells (M17) expressing PrP C (PrP C cells) were generated and maintained as described previously (Singh et al., 1997) . Human astrocytoma cell line SW1088 (SW) was obtained from American Type Culture Collection (Manassas, VA) (HTB-12) and cultured in DMEM supplemented with 10% fetal bovine serum. Scrapie-infected mouse neuroblastoma cells (ScN2a) were obtained from Dr. Byron Caughey (Rocky Mountain Laboratories) and maintained as specified by Dr. Gregory Raymond (Rocky Mountain Laboratories). Mouse neuroblastoma cells (N2a) were obtained from American Type Culture Collection. Culture supplies were obtained from Invitrogen (Carlsbad, CA), and hygromycin B was obtained from Calbiochem (San Diego, CA). Recombinant PrP was a kind gift from Dr. Witold Surewicz (Case Western Reserve University). Primary antibodies 3F4 and 8H4 against PrP were purchased from Signet Laboratories (Dedham, MA) and provided by Drs. Pierluigi Gambetti and Man-Sun Sy (National Prion Surveillance Center, Case Western Reserve University), anti-ferritin antibody was from Sigma-Aldrich (St. Louis, MO), horseradish peroxidase (HRP)-labeled secondary antibodies were from GE Healthcare (Little Chalfont, Buckinghamshire, United Kingdom), fluorescein isothiocyanate-(FITC) and tetramethylrhodamine B isothiocyanate (TRITC)-labeled secondary antibodies were from Southern Biotechnology Associates (Birmingham, AL), and mouse and rabbit peroxidase-anti-peroxidase were from Cappel Laboratories (Cochranville, PA). LysoTracker and Hoechst were obtained from Invitrogen, and the silver staining kit was from Bio-Rad (Hercules, CA). EZ-Link sulfosuccinimidyl 2-(biotinamido)-ethyl-1,3-dithiopropionate (Sulfo-NHS-biotin) and Texas Red-conjugated streptavidin were from Pierce Chemical (Rockford, IL), and 3,3Ј-diaminobenzidine (DAB) was from Invitrogen. All other chemicals, including ferrous chloride, were obtained from Sigma-Aldrich.
Iron Labeling of Recombinant PrP
Recombinant PrP (5 g in 20 l of sodium acetate buffer, pH 4.0) was mixed with 10 Ci of 59 FeCl 3 , and the pH was adjusted to 7.4 with 1 ml of phosphate-buffered saline (PBS), pH 8.0. The reaction mixture was incubated at room temperature for 3 h, and then it was dialyzed against excess PBS for 72 h.
Native Gradient Gel Electrophoretic Separation
Linear 3-18% polyacrylamide gel was prepared using Hoefer SG gradient maker as described with minor modifications (Vyoral et al., 1998) . The gel mixture contained 0.375 M Tris, pH 6.8, 1.5% Triton X-100, and 1.18 mM ammonium persulfate. N,N,NЈ,NЈ-Tetramethylethylenediamine was added to a final concentration of 5.38 mM for the 3% gel mixture and 2.69 mM for the 18% gel mixture. The prepared gel was left overnight at room temperature for polymerization. Radiolabeled PrP mixed with 5 l of glycerol was subjected to electrophoresis under constant current for 3 h at 4°C. The gel was vacuum-dried and exposed to Kodak BioMax XAR film in Kodak X-Omatic cassette (Eastman Kodak, Rochester, NY) fitted with Lanex Regular intensifying screens for 72 h to 1 wk at Ϫ70°C.
FeCl 2 Treatment
In a typical experiment, 7 ϫ 10 6 cells were exposed to 0.1, 0.2, or 0.3 mM FeCl 2 mixed in complete medium for 72 h (0.3 M stock in water). Subsequently, cells were washed three times with PBS and subcultured in 100-mm Petri dishes or on coverslips overnight in fresh medium lacking FeCl 2 before analysis.
Brain Tissue
Three cases each of normal (age 62-67 yr) and sCJD (age 60 -67 yr), and five each of normal and scrapie-infected mouse brains were used for analysis. Human brain tissue was obtained from Dr. Gambetti, and mouse brain tissue was harvested from scrapie-infected mice (22L) generated in our facility. Brain homogenates (10%) were prepared in PBS or in lysis buffer and frozen in small aliquots until use.
Biotinylation
Cell lysates or brain homogenates were biotinylated with 1 mg/ml sulfo-NHS-biotin in PBS overnight at 4°C, and excess biotin was quenched with 50 mM glycine followed by desalting in a spin column. Small aliquots of biotinylated samples were frozen until use.
Differential Centrifugation
Cells were exposed to 10 l of 10% NH or CJDH mixed in 5 ml of complete medium for 48 h or to desired concentrations of FeCl 2 for 72 h. Cells were then subjected to immunoprecipitation or differential centrifugation followed by Western blot analysis essentially as described previously (Singh et al., 1997) .
Detection of Redox Iron
Modified Prussian blue reaction was used to detect redox-active ferrous and ferric iron in brain and cell lysate samples as described previously (Smith et al., 1997) . Briefly, 5 l of 10% mouse and human brain homogenate or P 2 I fraction isolated from cells was dot blotted on a polyvinylidene difluoride (PVDF) membrane and allowed to dry at room temperature. Total protein concentration was 6.60 Ϯ 0.09 and 4.73 Ϯ 0.34 mg/ml in normal and sCJD samples, 10.71 Ϯ 0.30 and 7.37 Ϯ 0.22 mg/ml in normal and scrapie-infected mouse samples, and 6.78 Ϯ 0.37 and 5.99 Ϯ 0.14 mg/ml in -FeCl 2 P 2 I and ϩFeCl 2 P 2 I samples, respectively. Membranes were incubated overnight in 7% potassium ferrocyanide or potassium ferricyanide dissolved in 3% hydrochloric acid to detect ferric or ferrous iron, respectively. After the incubation, membranes were washed twice in distilled water for 5 min each and then incubated at room temperature with stable DAB containing 3% H 2 O 2 until brown-blue color developed.
Determination of Total Iron
A colorimetric method was used to estimate total iron in brain and cell lysate samples according to the manufacturer's instructions (Teco Diagnostics, Anaheim, CA). Briefly, 200 l of 10% brain homogenate or P 2 I sample was dissolved in 1 ml of acetate buffer containing 220 mM hydroxylamine hydrochloride, pH 4.5, and 50 l of 16.6 mM ferrozine. Change in color was recorded at 560 nm after 10 min of incubation at 37°C by using 500 mg/dl FeCl 2 solution as standard.
Treatment with Desferroxamine (DFO)
To chelate iron from brain homogenates, 10% homogenate of sCJD and mouse scrapie prepared in PBS was exposed to 100 M DFO or vehicle for 10 min at room temperature, followed by extensive dialysis against PBS for 72 h. Subsequently, untreated and DFO-treated samples were supplemented with 10ϫ lysis buffer before proteinase K digestion. For DFO exposure of ScN2a cells, semiconfluent (ϳ70%) cultures were supplemented with 5 and 10 M DFO or vehicle in serum-free medium for 24 h, washed in PBS, and harvested for PK treatment followed by Western blotting. (Surprisingly, DFO-treated cells looked healthier than vehicle-treated control cells at the end of 24 h.)
Immunostaining and Confocal Microscopy
Control and treated PrP C cells were prepared for confocal microscopy as described in previous reports (Singh et al., 1997; Mishra et al., 2004) .
RESULTS
Prion Disease-affected Human and Mouse Brains Show Increased Reactivity for Redox Iron
Because imbalance in iron homeostasis and markers of oxidative stress are a common feature of prion disease-affected brains and cultured cells (Kim et al., 2000; Wong et al., 2001; Fernaeus and Land, 2005) , the amount of redox-active ferrous and ferric iron in mouse and human normal brain homogenate (NH), scrapie-infected mouse homogenate (ScH), and sporadic Creutzfeldt-Jakob disease-affected brain homogenate (CJDH) was estimated by reacting 5 l of 10% brain homogenate spotted on a PVDF membrane with potassium ferri-and ferrocyanide, respectively, followed by incubation with DAB and H 2 O 2 (modified Perl's reaction) (Smith et al., 1997) . A brown reaction product with or without blue iron granules is indicative of a positive reaction. Remarkably, both ScH and CJDH samples show strong reactivity for ferrous and ferric iron compared with agematched controls ( Figure 1A) . Quantification of total ferrozine-releasable iron shows four-to sixfold more iron in ScH and CJDH samples compared with age-matched controls ( Figure 1B ). To evaluate whether ferrous iron in CJDH is biologically active, 10 l of biotin-tagged NH or CJDH (10% in PBS) was added to the culture medium of PrP C cells. After 48 h, cell lysates were subjected to differential centrifugation followed by SDS-polyacrylamide gel electrophoresis (PAGE) and immunoblotting with anti-PrP antibody 3F4. Normally, PrP C partitions almost exclusively in the detergent-soluble low-and high-speed supernatant fractions (S 1 I, S 2 I), whereas aggregated PrP Sc -like forms are detected in the high-speed detergent-insoluble pellet fraction (P 2 I). Nuclei and cell debris sediment in the low-speed pellet (P 1 I) frac-tion. In the NH-treated sample, almost all of PrP C fractionates in the detergent-soluble S 1 I and S 2 I fractions ( Figure 1C , lanes 1-4). In contrast, a significant amount of PrP C from CJDH-exposed lysates sediments in the detergent-insoluble P 2 I fraction ( Figure 1C , lanes 5-8). Reprobing with antiferritin shows slight up-regulation of ferritin and a prominent ferritin band in P 2 I fraction of CJDH-exposed lysates ( Figure 1D, lanes 1-8, arrow) . Reaction of the same membrane with streptavidin shows no overlap of biotin-tagged proteins with PrP or ferritin (Supplemental Figure 1) , confirming that aggregated PrP and ferritin in the P 2 I fraction are from the cellular pool, not from added homogenate. Up-regulation of ferritin in CJDH-exposed PrP C cells could be due to uptake of bioavailable ferrous iron from the sample, especially from the PrP Sc -ferritin complex (Mishra et al., 2004) , or induction of stress due to other factors. Alternately, PrP Sc itself could act as a source of iron, especially if PrP C binds iron (Thompsett et al., 2005) . To investigate this possibility, recombinant PrP lacking His-tag (Morillas et al., 1999) was radiolabeled with 59 FeCl 3 -acetate complex and fractionated on an iron gel essentially as described previously (Vyoral et al., 1998) . A prominent iron-labeled PrP band is noted in the native gel ( Figure 1E , lane 1), demonstrating that purified PrP binds iron. Silver staining of the same sample evaluated in parallel reveals a negative stain for PrP due to bound iron, although minor bands that probably represent degradation products and do not bind iron show a positive stain with silver ( Figure 1E , lane 2). Frac- brain homogenate from normal human and mouse (NH), scrapie-infected mouse (ScH), and sCJD were blotted on PVDF membrane and reacted for ferrous and ferric iron (Smith et al., 1997) . In contrast to NH, ScH and CJDH show strong reactivity for ferrous iron [Fe(II)]. Ferric iron is detected in all samples, but significantly more is in ScH and CJDH samples [Fe(III)]. (B) Colorimetric quantification of total iron shows four-to sixfold more iron in ScH and CJDH samples compared with age-matched NH controls. Unpaired t test shows highly significant mean difference between normal and diseased samples. Values for mouse samples: ⌬mean ϭ 36.7; 95% confidence interval (CI) ϭ 44.3, 29.2; t ϭ 13.5; df ϭ 8; p Ͻ 0.0002. Values for human samples: ⌬mean ϭ 25.5; 95% CI ϭ 29.2, 21.9; t ϭ 19.6; df ϭ 4; p Ͻ 0.0001). (C) Lysates of PrP C cells exposed to biotin-tagged NH or CJDH were subjected to differential centrifugation and immunoblotted with 3F4. In NH-exposed lysates, most of PrP C fractionates in the detergentsoluble S 1 I and S 2 I fractions (lanes 1 and 3). Minimal amounts of unglycosylated PrP C are detected in the low-and high-speed detergent-insoluble fractions P 1 I and P 2 I (lanes 2 and 4). In contrast, CJDH-treated lysates show a significant amount of PrP in the highspeed detergent-insoluble P 2 I fraction (lanes 5-8).
(D) Reprobing with anti-ferritin shows slight upregulation of ferritin in CJDH-treated lysates, 40% of which partitions in the P 2 I fraction (lanes 1-8, arrow). (E) Recombinant PrP radiolabeled with 59 FeCl 3 -acetate complex shows a prominent ironlabeled band on native iron gel (lane 1) that shows a negative stain when stained with silver due to bound iron (lane 2). Minor bands that stain with silver probably represent degradation products that do not bind iron. Fractionation on SDS-PAGE and silver staining shows a single prominent band of recombinant PrP (lane 3). (F) M17 and PrP C cells were radiolabeled with 59 FeCl 3 -citrate complex for 4 h and subjected to immunoprecipitation with 3F4 and 8H4. Eluted proteins were spotted on PVDF membrane followed by autoradiography. (G) Quantification of iron-labeled proteins in the immunoprecipitate by direct gamma-counting. n ϭ 5. Unpaired t test shows highly significant mean difference between iron-labeled PrP immunoprecipitated from M17 and PrP C cells. Values for 3F4 immunoprecipitates: ⌬mean ϭ 313.1; 95% CI ϭ 348.9, 277.3; t ϭ 24.3; df ϭ 8; p Ͻ 0.0001. Values for 8H4 immunoprecipitates: ⌬mean ϭ 362.5; 95% CI ϭ 404.2, 320.8; t ϭ 24.15; df ϭ 8; p Ͻ 0.0001.
tionation of the same sample on SDS-PAGE that strips iron due to boiling in SDS shows a single prominent band by silver staining, confirming the purity of the sample ( Figure  1E , lane 3). To check whether cell-associated PrP C binds iron, nontransfected neuroblastoma cells (M17) and M17 cells transfected to express six-to eightfold more PrP C (PrP C cells) were incubated with 59 FeCl 3 -citrate complex for 4 h and processed for immunoprecipitation with 3F4 and 8H4. After stringent washing of beads, bound proteins were eluted with boiling SDS-sample buffer and counted directly in a gamma-counter. Subsequently, an aliquot of the same sample was dot-blotted on a PVDF membrane followed by autoradiography, and an equal amount was subjected to Western blotting to eliminate contamination with major iron-binding proteins such as ferritin and transferrin. As noted for recombinant PrP, cell-associated PrP C shows significant incorporation of 59 Fe into PrP C (Figure 1 , F and G), and the signal is not derived from coimmunoprecipitated ferritin or transferrin (Supplemental Figure 2) . Together, these data demonstrate increased levels of biologically active redox iron and a state of oxidative stress in prion disease-affected brains. In addition, PrP C seems to bind iron, suggesting that the change in conformation of PrP C to PrP Sc with consequent sequestering of PrP C -bound iron may account for brain iron imbalance. Because brain presents a complex milieu that is difficult to manipulate experimentally, further investigations aimed at understanding the role of redox iron in prion disease pathogenesis were carried out on PrP C cells.
Exposure of PrP C Cells to Redox Iron Induces the Accumulation of PrP
In a previous report, 0.3 mM inorganic ferrous chloride (FeCl 2 ) has been used successfully to induce oxidative damage to ␣-synuclein in a cell model (Ostrerova-Golts et al., 2000) . To identify the optimum concentration of FeCl 2 as close to the in vivo situation as possible, PrP C cells were exposed to 0, 0.2, and 0.3 mM FeCl 2 in complete medium for 72 h, and cell lysates were compared with freshly harvested NH and ScH for cleavage of protein kinase C (PKC)␦ into its catalytically active fragment as a positive marker of oxidative stress (Kaul et al., 2003) . Western blotting with anti-PKC␦ antibody reveals full-length 74-kDa PKC␦ protein in NH and in cells exposed to 0 and 0.2 mM FeCl 2 (Supplemental Figure 3 , A and B). In contrast, ScH and lysates from cells exposed to 0.3 mM FeCl 2 show the catalytically active 41-kDa fragment of PKC␦, indicating that 0.3 mM FeCl 2 simulates the in vivo conditions of oxidative stress within the limitations of this method. An additional fragment of 25 kDa of unknown significance is also noted in ScH and 0.3 mM FeCl 2 -exposed samples (Supplemental Figure 3B) . Reprobing of cell lysates with 3F4 shows the expected glycoforms of PrP C migrating at 27, 28 -30, and 37 kDa in untreated lysates (Figure 2A Figure 2B , lanes 2 and 3). The difference in PrP C and ferritin levels is not due to differential loading as determined by silver staining of the membrane after immunoblotting (data not shown). Morphological evaluation of PrP C cells exposed to vehicle or 0.3 mM FeCl 2 was carried out by immunoreacting permeabilized cells with 3F4, 8H4, or anti-ferritin followed by appropriate peroxidase-conjugated secondary antibodies and reaction with DAB. Vehicle-treated cells show normal distribution of PrP C on the plasma membrane and in the Golgi area with both 3F4 and 8H4 ( Figure 2C, 1 and 3) . In contrast, cells exposed to FeCl 2 show barely detectable immunoreactivity with 3F4 ( Figure 2C2 ) and strong intracellular reaction with 8H4 ( Figure 2C4 ). Similar evaluation with anti-ferritin shows strong intracellular reaction in FeCl 2 -exposed cells compared with vehicle-treated controls ( Figure 2C , 5 and 6), whereas nuclear morphology remains unaltered ( Figure 2C , 1-6). C cells were permeabilized and immunoreacted with 3F4, 8H4, or anti-ferritin antibodies. After incubation with appropriate peroxidase-conjugated secondary antibodies, the cells were reacted with DAB and observed. Mock-treated cells show PrP reaction in the Golgi region with both 3F4 and 8H4 antibodies (1 and 3). In contrast, FeCl 2 -treated cells do not react with 3F4, but they show a strong reaction with 8H4 (panels 2 and 4). Strong reactivity for ferritin is observed in FeCl 2 exposed cells in comparison to mock-treated controls (5 and 6). Figure 1C . As expected, PrP C from mock-treated lysates partitions almost exclusively in the detergent-soluble S 1 I and S 2 I fractions ( Figure 3A, lanes  1-4) . In contrast, PrP C from FeCl 2 -exposed cells partitions in the low-speed pellet P 1 I and high-speed pellet P 2 I fractions ( Figure 3A, lanes 5-8) . Reprobing with anti-ferritin reveals 8-to 10-fold up-regulation of ferritin in treated cells, 40% of which partitions in the P 2 I fraction ( Figure 3B, lanes 1-8) . Quantification reveals an increase in detergent-insoluble PrP from 28 to 55% after exposure to FeCl 2 (Supplemental Figure  4) . Reprobing with anti-␤-actin shows no effect of FeCl 2 on ␤-actin expression or detergent solubility, and equivalent protein loading in all lanes ( Figure 3C, lanes 1-8) . Sensitivity to PK was estimated by treating mock-and FeCl 2 -exposed lysates to 0, 7.5, and 15 g/ml PK for 5 min at 37°C. The reaction was stopped with 4 mM phenylmethylsulfonyl fluoride, and PK-resistant PrP was visualized by immunoblotting with 3F4. Mock-treated lysates show the expected glycoforms of PrP C , all of which are digested by 7.5 g/ml PK ( Figure 3D, lanes 1-3) . In contrast, FeCl 2 -treated lysates show limited resistance of PrP to PK and the generation of a 20-kDa C-terminal fragment ( Figure 3D, lanes 4 -6) . Reprobing with anti-ferritin reveals up-regulation of ferritin and resistance to digestion with 7.5 and 15 g/ml PK, although a minor fraction is cleaved and releases a fragment of ϳ14 kDa ( Figure 3E, lanes 1-6) . To evaluate whether change in conformation of PrP C to a PrP Sc -like form (*PrP Sc ) as evidenced by detergent insolubility and PK resistance is a direct effect of redox iron, a similar evaluation was carried out on human astrocytoma cell line (SW) that expresses ceruloplasmin on the plasma membrane, a protein known to shuttle excess iron and copper ions out of the cell (Patel and David, 1997) . Differential centrifugation of mock-and FeCl 2 -exposed SW cells does not reveal aggregation or up-regulation of PrP C or ferritin, confirming a direct role of redox iron in this process (Supplemental Figure 5, A and B, lanes 1-8) . Together, the above-mentioned data demonstrate that exposure of neuroblastoma cells to redox iron causes a change in conformation of PrP C to *PrP Sc . Astrocytes provide a protective environment for PrP C under these circumstances due to their inherent capacity to shuttle excess iron out of the cells, a property lacking in neuroblastoma cells.
Ferrous Iron-induced *PrP
Sc Is Associated with Ferritin In a previous study, we reported that PrP Sc and ferritin form a complex in brain homogenates of sCJD cases (Mishra et al., 2004) . To identify the presence of a similar complex in our model, mock-and FeCl 2 -exposed cells were coimmunostained with 8H4-anti-mouse FITC and anti-ferritin-anti-rabbit TRITC. (To eliminate autofluorescence, cells were washed and cultured overnight in medium lacking FeCl 2 .) In mock-treated cells, distinct PrP C and ferritin reaction is detected in the Golgi area and cytosol, respectively ( Figure  4A, 1-3 ). In FeCl 2 -treated cells, in contrast, PrP and ferritin reaction is severalfold higher, and both proteins colocalize in intracellular vesicular structures ( Figure 4A , 4 -6, arrows). Reaction of FeCl 2 -exposed cells with the lysosome-specific dye LysoTracker and 8H4-anti-mouse FITC shows localization of PrP within lysosomes ( Figure 4B, 1-3, arrows) . To evaluate whether PrP and ferritin are associated with each other within lysosomes, PrP C cells exposed to 0, 0.2, or 0.3 mM FeCl 2 for 72 h were lysed in nondenaturing buffer and immunoprecipitated with 8H4 or anti-ferritin antibodies. Eluted proteins were fractionated by SDS-PAGE and immunoblotted with 3F4. In 8H4 immunoprecipitates, as expected, normal glycoforms of PrP C are detected. It is notable that the intensity of all PrP C glycoforms increases after FeCl 2 exposure as noted in Figure 2A (Supplemental Figure 6,  lanes 1-3) . Surprisingly, anti-ferritin immunoprecipitates of treated lysates pull down all three glycoforms of PrP C , especially the unglycosylated form that almost doubles in intensity when FeCl 2 is increased from 0.2 to 0.3 mM (Supplemental Figure 6 , lanes 5 and 6, arrowhead). A small amount of PrP C from untreated lysates also coimmunoprecipitates with anti-ferritin, a reproducible finding that is currently under investigation (Supplemental Figure 6 , lane 4). Control immunoprecipitates in the absence of antibodies do not reveal any detectable bands with 8H4 or anti-ferritin, ruling out nonspecific binding to protein A beads (Supplemental Figure 6, lanes 7-9) . The difference in PrP signal in Figure 3 . (A) Mock-and 0.3 mM FeCl 2 -exposed cell lysates were fractionated by differential centrifugation and immunoblotted with 3F4. As expected, the majority of PrP C from mock-treated lysates partitions in the detergent-soluble S 1 I and S 2 I fractions (lanes 1 and 3), with minimal amounts in the P 1 I and P 2 I fractions (lanes 2 and 4). In contrast, significant amounts of PrP C from FeCl 2 -treated lysates are detected in the pellet fractions P 1 I and P 2 I (lanes 6 and 8). A minor 20-kDa fragment is observed in the P 1 I fraction of treated cells (lane 6). (B) Reprobing with anti-ferritin shows up-regulation of ferritin in FeCl 2 -treated lysates (lanes 1-8), 40% of which partitions in the P 2 I fraction (lane 8). (C) FeCl 2 treatment has no detectable effect on the expression or solubility of ␤-actin. (D) Treatment of lysates prepared from mock-and FeCl 2 -exposed cells with 7.5 and 15 g/ml PK results in the complete digestion of PrP C in mock-treated controls (lanes 1-3) , whereas treated lysates show a 20-kDa PK-resistant fragment (lanes 4 -6). (E) Reprobing with antiferritin shows up-regulation of ferritin in FeCl 2 -exposed cells (lanes 1-6) and the generation of a 14-kDa fragment by PK (lanes 5 and 6, arrow). lanes 2 and 3 is due to aggregation of PrP C and coimmunoprecipitation with anti-ferritin when exposed to 0.3 mM FeCl 2 (Supplemental Figure 4) . Thus, *PrP Sc and ferritin form a coimmunoprecipitable complex in FeCl 2 -exposed cells.
Ferrous Chloride-induced *PrP
Sc -Ferritin Complex Propagates *PrP Sc Conformation Brain-derived PrP Sc has the unique capability of inducing a similar change in neighboring PrP C , resulting in PrP Sc replication. To evaluate whether *PrP Sc induced by FeCl 2 can induce the aggregation of additional PrP C , lysates of mocktreated (ϪFeCl 2 ) and FeCl 2 -exposed (ϩFeCl 2 ) cells were biotinylated, subjected to differential centrifugation, and the P 2 I fraction was resuspended in 400 l of PBS. Subsequently, 5 l of biotin-tagged -FeCl 2 P 2 I and ϩFeCl 2 P 2 I was added to the culture medium of PrP C cells for 72 h, and lysates were fractionated by differential centrifugation as described above. (For clarity, protein fractions obtained from cells exposed to P 2 I are identified with the roman II.) Immunoblotting with 3F4 shows almost all PrP in the detergentsoluble S 1 II and S 2 II fractions of ϪFeCl 2 P 2 I-exposed cells, as in Figure 3A ( Figure 5A, lanes 1-4) . In contrast, exposure to ϩFeCl 2 P 2 I results in a significant shift of PrP to the detergent-insoluble P 1 II and P 2 II fractions ( Figure 5A , lanes 6 and 8). Reprobing with anti-ferritin shows 8-to 10-fold up-regulation of ferritin in cells exposed to ϩFeCl 2 P 2 I, 60% of which is detected in the P 2 II fraction ( Figure 5B, lanes 5-8) .
Reprobing with anti-␤-actin shows no alteration of ␤-actin levels in ϪFeCl 2 P 2 I-and ϩFeCl 2 P 2 I-exposed cell lysates ( Figure 5C, lanes 1-8) . Reaction with streptavidin-HRP shows that added biotin-tagged ϩFeCl 2 P 2 I is endocytosed by PrP C cells and sediments in the P 1 II fraction ( Figure 5D , lane 6). It is notable that biotin-tagged material is absent from ϪFeCl 2 P 2 I-exposed cells, suggesting that either ϪFeCl 2 P 2 I is not internalized at all, or is degraded after endocytosis. The detergent-insoluble PrP in the P 2 II fraction of ϩFeCl 2 P 2 I-exposed cells, therefore, represents newly aggregated *PrP Sc induced by the treatment. Next, sensitivity of lysates prepared from cells exposed to 0.3 mM FeCl 2 , ϩFeCl 2 P 2 I, and ϪFeCl 2 P 2 I to limited digestion with PK was assessed. After treatment with 0, 7.5, and 15 g/ml PK for 5 min at 37°C, PK-resistant PrP was detected by immunoblotting with 3F4. Remarkably, both 0.3 mM FeCl 2 and ϩFeCl 2 P 2 I result in the generation of a 20-kDa C-terminal PKresistant fragment typical of disease-associated PrP Sc ( Figure  5E , lanes 4 -6 and 10 -12), whereas PrP from mock-treated and ϪFeCl 2 P 2 I-exposed cells is completely degraded (Figure 5E , lanes 1-3 and 7-9). A comparison of protein fractions isolated from ϪFeCl 2 P 2 I-and ϩFeCl 2 P 2 I-exposed lysates shows up-regulation of proteins in the 100-and 10-to 35-kDa range in the ϩFeCl 2 P 2 II fraction (Supplemental Figure  7) . Total iron content of the two fractions is 0.008 and 0.12 mM, respectively (Supplemental Figure 8B) . However, exposure of PrP C cells to 0.1 and 0.2 mM FeCl 2 for 72 h does not result in the aggregation or PK resistance of PrP C ( Figure  5 , F and G), indicating that ϩFeCl 2 P 2 I-induced aggregation and PK resistance of additional PrP C is not simply due to the iron content of this fraction. Cellular localization and physical proximity of PrP aggregates to ϩFeCl 2 P 2 I was evaluated by immunostaining permeabilized cells with streptavidin-Texas Red to identify added P 2 I and 8H4-FITC to visualize endogenous PrP. All cells show variable sizes of streptavidin-reactive P 2 I aggregates on the cell surface and in endocytic vesicles ( Figure 5H, 1-3 ). Higher magnification image of two cells from images 1 to 3 shows P 2 I-induced coaggregation of endogenous PrP ( Figure 5H , 4 -6), whereas other cells show distinct reaction for P 2 I and PrP with limited or no colocalization (Figure 5H, (7) (8) (9) . Most treated cells show increased immunoreaction for PrP, indicating ϩFeCl 2 P 2 I-induced up-regulation as noted for FeCl 2 -treated cells ( Figure 5H, 1-9 ). Coimmunostaining with anti-ferritin and anti-PrP antibodies shows partial colocalization of the two proteins as observed in Figure 4A ( Figure 5H, 10 -12 ). To evaluate whether the above-mentioned results are due to the redox-active nature of ϩFeCl 2 P 2 I, ferrous and ferric iron content of 5 l of ϪFeCl 2 P 2 I and ϩFeCl 2 P 2 I was analyzed as described in Figure 1A . In comparison with ϪFeCl 2 P 2 I, the ϩFeCl 2 P 2 I sample shows significantly higher ferrous and ferric iron reactivity (Supplemental Figure 8A) . Quantitative analysis of the total iron pool shows 12-fold more iron in ϩFeCl 2 P 2 I compared with ϪFeCl 2 P 2 I sample (Supplemental Figure 8B) , and 3-4 times more iron than ScH and sCJDH, respectively (compare with Figure 1B) . Together, the above-mentioned results demonstrate that exposure of PrP 4) . In contrast, a significant proportion of PrP C from ϩFeCl 2 P 2 I lysates shifts to the detergent-insoluble P 1 II and P 2 II fractions (lanes 5-8). (B) Reprobing with anti-ferritin shows up-regulation and shift to P 2 II fraction of a significant amount of ferritin in the ϩFeCl 2 P 2 I-exposed sample (lanes 1-8) .
Depletion of Iron Reduces PK-resistant PrP Sc in Diseased Tissue and Infected Cells
To evaluate the influence of iron on infectious PrP Sc , sCJDand scrapie-infected mouse brain homogenates prepared in PBS were treated with vehicle or 100 M DFO for 5 min at room temperature, and the samples were dialyzed extensively against PBS for 72 h. Recovered sCJD samples were subjected to another round of DFO treatment and dialysis, whereas mouse brain samples were analyzed as such. After dialysis, an aliquot of each was spotted on a PVDF membrane to assess ferrous and ferric iron content in untreated and DFO-treated samples (Figure 6, D and H) , and an additional aliquot was supplemented with detergent, exposed to PK, and analyzed by Western blotting. Immunoblotting of control and DFO-treated sCJD homogenate with 3F4 shows the expected glycoforms of PrP migrating between 27 and 40 kDa ( Figure 6A, lanes 1 and 2) . Treatment with 100 g/ml PK for 1 h at 37°C results in the generation of C-terminal PK-resistant fragments of PrP Sc in the untreated control, whereas DFO-treated sample shows almost complete absence of PK-resistant PrP Sc ( Figure 6A , lanes 3 and 4, white arrow). Reprobing for ferritin shows no apparent difference between control and DFO-treated samples ( Figure 6B , lanes 1 and 2), although PK treatment of DFO-treated sample causes slight decrease in monomeric ferritin migrating at 20 kDa and disappearance of some oligomeric forms ( Figure  6B , lanes 3 and 4, arrowhead). Silver staining of PK-treated samples confirms that the difference in PrP and ferritin reactivity noted above is not an artifact of loading ( Figure  6C, lanes 3 and 4) . (The membranes were not probed for ␤-actin because PK cleaves this protein (data not shown). Reaction of control and DFO-treated samples for ferrous and ferric iron shows significant reduction of both forms, especially ferric iron after DFO treatment ( Figure 6D ). Quantification from four independent evaluations shows a decrease in PK-resistant PrP Sc and ferritin from 99 to 10% and from 100 to 80%, respectively, after DFO treatment ( Figure 6E ). Similar evaluation of scrapie-infected mouse brain homogenate shows a significant decrease in PK-resistant PrP Sc after DFO treatment ( Figure 6F, lanes 1-4, white arrow) . Reprobing for ferritin shows, surprisingly, generation of monomeric ferritin by merely DFO treatment ( Figure 6G , lane 2, black arrow). Exposure to PK results in degradation of monomeric ferritin regardless of DFO treatment ( Figure 6G,  lanes 3 and 4) , and disappearance of a minor band after DFO exposure ( Figure 6G, lanes 2 and 4, arrowhead) . Quantification from four independent experiments shows a decrease in PK-resistant PrP Sc from 98 to 25% and no significant change in ferritin, regardless of DFO treatment ( Figure 6I) . The relatively less effect of DFO on PK sensitivity of mouse PrP Sc compared with sCJD is perhaps due to reduced chelation of iron from these samples (Figure 6, H vs. D) . The differential PK sensitivity of ferritin monomers and oligomers from human and mouse brains is unclear from our data. To determine whether depletion of iron has similar effect on ScN2a cells that actively replicate and accumulate infectious PrP Sc in culture, cells were exposed to vehicle or 5 and 10 M DFO in serum-less medium for 24 h and harvested in a buffer containing nonionic detergents. Lysates containing equivalent protein were treated with 7.5 and 15 g/ml PK for 5 min at 37°C, and methanol-precipitated proteins were fractionated by SDS-PAGE and transferred to PVDF membrane. To ensure equal loading, transferred proteins were visualized by staining with Ponsue Red (Supplemental Figure 9 ) followed by immunoblotting with 8H4 and antiferritin. Probing with ␤-actin was omitted, because PK cleaves this protein. Reaction with 8H4 shows the expected glycoforms of PrP that are relatively resistant to digestion by 7.5 and 15 g/ml PK, although some sensitivity is observed at the higher dose ( Figure 7A, lanes 1-3) . (This is expected because PrP Sc from this cell line is cleaved by 20 g/ml PK for 60 min at 37°C; Taraboulos et al., 1990 .) Similar evaluation of lysates prepared from DFO-treated cells shows a dose-dependent decrease in PK-resistant PrP Sc ( Figure 7A , lanes 4 -9). Reprobing for ferritin shows slight PK sensitivity of oligomeric and monomeric ferritin regardless of DFO treatment ( Figure 7B, lanes 1-9) . Some forms decrease in intensity ( Figure 7B , lanes 1-9, black arrows), whereas others increase as higher order oligomers are reduced to lower order complexes (lanes 1-9, white arrowhead). Quantification from four independent experiments shows a significant decline in PK-resistant PrP Sc from 99 to 70% and from 70 to 40% with 7.5 and 15 g/ml PK, respectively, after exposure to 5 M DFO. A further decline of PK-resistant PrP Sc to 30 and 18% is observed when the DFO concentration is increased to 10 M ( Figure 7C ). Similar quantification of ferritin shows 75-95% PK-resistant ferritin regardless of DFO treatment ( Figure 7D) . To rule out possible cytotoxicity by DFO, viability of N2a and ScN2a cells exposed to 10 M DFO or vehicle for 24 h was quantified by terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) staining. Twenty random 20ϫ microscopic fields were examined, and the percentage of TUNNEL-positive cells was calculated. Based on these results, DFO-treated N2a cells show a slight increase in cell death in comparison with untreated controls from 5 to 8%, whereas similarly treated ScN2a cells show a reduction in cell death from 10 to 5%, respectively (data not shown). Surprisingly, iron chelation seems to improve the viability of ScN2a cells. Thus, depletion of iron from infectious brain homogenates or scrapieinfected cells reduces the total amount of PK-resistant PrP Sc to a significant extent. Notably, ferritin does not show a 8) . (D) Reaction of the same membrane with streptavidin-HRP shows biotin-tagged proteins only in the P 1 II fraction of ϩFeCl 2 P 2 I-exposed sample (lane 6). (E) Treatment of mock-, 0.3 mM FeCl 2 -, ϪFeCl 2 P 2 I-, or ϩFeCl 2 P 2 I-treated lysates with 7.5 and 15 g/ml PK shows complete digestion of PrP C in mock-and -FeCl 2 P 2 I-exposed samples (lanes 1-3 and 7-9). In contrast, 0.3 mM FeCl 2 -and ϩFeCl 2 P 2 I-exposed samples show partial resistance to 7.5 g/ml PK, resulting in the generation of a 20-kDa fragment (lanes 4 -6 and 10 -12). (F) Lysates of PrP C cells exposed to 0, 0.1, 0.2, and 0.3 mM FeCl 2 for 72 h were subjected to differential centrifugation and immunoblotting with 3F4. The majority of PrP C from cells exposed to 0, 0.1, and 0.2 mM FeCl 2 fractionates in the detergent-soluble S 1 I and S 2 I fractions (lanes 1-12) . In contrast, a significant proportion of PrP C from cells exposed to 0.3 mM FeCl 2 shifts to the detergent-insoluble P 1 I and P 2 I fractions (lanes 13-16). (G) Treatment of lysates from F above with 7.5 and 15 g/ml PK shows complete digestion of PrP C from samples exposed to 0, 0.1, and 0.2 mM FeCl 2 (lanes 1-9). In contrast, the sample exposed to 0.3 mM FeCl 2 shows partial resistance to 7.5 and 15 g/ml PK, resulting in the generation of 20-kDa C-terminal fragment (lanes 10 -12). (H) PrP C cells exposed to biotin-tagged ϩFeCl 2 P 2 I were permeabilized and reacted with 8H4-anti-mouse FITC and streptavidin-Texas Red. Streptavidin-positive aggregates are detected on the plasma membrane and in endocytic vesicles (1-3). Higher magnification of select cells from 1 to 3 shows aggregation of PrP around streptavidin-positive aggregates in some areas (4 -6) and distinct PrP and streptavidin reaction in other regions (7-9). All cells show upregulation of PrP (1-9). Coimmunostaining with 8H4-anti-mouse FITC and anti-ferritin-anti-rabbit TRITC shows colocalization of the two proteins in vesicular structures near the Golgi region (10 -12).
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DISCUSSION
We demonstrate that exposure of PrP C cells to a source of redox iron results in the generation of *PrP Sc , a PrP Sc -like molecule that induces a similar change in additional PrP C when added to fresh cells. More importantly, depletion of iron from human and mouse infectious brain homogenates reduces the amount of PK-resistant PrP Sc , implicating redox iron in the generation, propagation, and stability of PKresistant PrP Sc . Although a change in conformation of recombinant and purified PrP C to a PrP Sc -like molecule has been reported by other groups by using a variety of in vitro reaction conditions (see below), this is the first demonstration where generation and propagation of a PrP Sc -like molecule has been achieved by an inorganic trigger in cells, a model that is biologically relevant and provides mechanistic insight into the process. Our data demonstrating the affinity of PrP C for iron raises several questions concerning PrP Sc propagation and prion disease pathogenesis. It is evident that PrP C changes to *PrP Sc when exposed to redox iron, an event most likely modulated by PrP C -bound iron. Metals such as iron and copper are known to interact with specific proteins, and they are reduced in their presence, resulting in protein aggregation and concomitant generation of highly toxic reactive oxygen species, H 2 O 2 , and hydroxyl radical (OH ⅐ ) (Behl et al., 1994) . Initiation of such a reaction between free radicals and PrP C -bound iron could explain the conversion of PrP C to PrP Sc . Highly reactive radicals released during the process would account for the change of additional PrP C to PrP Sc and associated neurotoxicity. Our data demonstrating the generation of redox-active *PrP Sc -ferritin 2) . However, DFO-treated samples show slight increase in sensitivity to PK, especially of oligomeric forms (lanes 3 and 4, arrowhead). (C) Silver staining shows equal amount of protein in PK-treated control and DFOtreated samples (lanes 3 and 4) . (D) Reaction for ferrous and ferric iron in sCJD samples shows significant reduction in especially the ferric form after DFO treatment. (E) Quantification from four independent evaluations shows a decrease in PK-resistant PrP Sc and ferritin from 99 to 10% and from 100 to 80%, respectively, after DFO treatment. n ϭ 4. Unpaired t test shows highly significant mean difference between PK-resistant PrP and ferritin in untreated and DFO-treated CJDH. Values for PK-resistant PrP: ⌬mean ϭ 95.2; 95% CI ϭ 78.8, 111.6; t ϭ 12.3; df ϭ 6; p Ͻ 0.0001. Values for PK-resistant ferritin: ⌬mean ϭ 21.6; 95% CI ϭ 419.5, 23.7; t ϭ 22.0; df ϭ 6; p Ͻ 0.0001. (F) Immunoblotting of mouse scrapie brain homogenate with 8H4 shows the expected glycoforms of PrP Sc in control and DFO-treated samples (lanes 1 and 2). After PK treatment, a significant amount of PrP Sc from DFO-treated samples undergoes degradation (lanes 3 and 4) . (G) Reprobing for ferritin shows prominent oligomers of ferritin migrating between 35 and 55 kDa (lanes 1 and 2), some of which are sensitive to DFO and give rise to monomeric ferritin migrating at 20 kDa (lane 2, black arrow). Treatment with PK shows increased sensitivity of monomeric and DFO-treated oligomeric forms of ferritin (lanes 3 and 4, arrowhead) (*, artifact of blotting). (H) Reaction of mouse brain homogenate for ferrous and ferric iron shows significantly less reactivity after DFO treatment. (I) Quantification shows a decrease in PK-resistant PrP Sc from 98 to 25% after DFO treatment. Ferritin does not show a significant difference before or after DFO treatment. n ϭ 4. Unpaired t test shows highly significant mean difference between PK-resistant PrP, and less significant difference between PK-resistant ferritin in untreated and DFO-treated mouse scrapie samples. Values for PK-resistant PrP: ⌬mean ϭ 69.2; 95% CI ϭ 56.4, 82.0; t ϭ 11.4; df ϭ 6; p Ͻ 0.0001. Values for PK-resistant ferritin: ⌬mean ϭ 24.0; 95% CI ϭ 36.6, 11.5; t ϭ 4.0; df ϭ 6; p Ͻ 0.0009. complexes by exposing PrP C cells to FeCl 2 and generation of additional *PrP Sc by these complexes supports this hypothesis. Although the *PrP
Sc induced by FeCl 2 shows 10-fold less PK resistance than brain-derived PrP Sc , it resembles the latter in several biochemical and biophysical characteristics such as insolubility in nonionic detergents, generation of the typical 19-to 20-kDa C-terminal fragment on PK treatment, and nonreactivity with 3F4 unless denatured. It is notable that similar treatment of astrocytes that possess redox-shuttling proteins such as ceruloplasmin in their plasma membrane does not result in up-regulation or aggregation of PrP C or ferritin in response to FeCl 2 . Likewise, transfection of PrP C cells with ceruloplasmin significantly reduces intracellular *PrP Sc (our unpublished observations), indicating that accumulation of *PrP Sc is a consequence of redox ironmediated insult. The greater propensity for unglycosylated PrP to aggregate in response to FeCl 2 supports previous observations suggesting a protective role of glycans in preventing the conformational change of PrP C to PrP Sc (Lehmann and Harris, 1997) . Although one may argue that redox iron levels in FeCl 2 far exceed those in prion-affected brains, it is notable that similar cleavage of PKC␦ to its catalytically active fragment is observed under both conditions, and the total iron in *PrP Sc isolated from FeCl 2 -exposed cells does not exceed the level in diseased brains significantly. Moreover, treated cells do not show any evidence of toxicity, and they revert back to normal morphology within 7 d of culture in normal medium, excluding direct toxicity as a cause of *PrP Sc formation. Similar doses of FeCl 2 have been used to demonstrate sensitivity of ␣-synuclein to oxidative stress in cell culture models (Ostrerova-Golts et al., 2000) , and other stressors such as H 2 O 2 used at a concentration of 100 -200 M in experimental paradigms of oxidative damage to PrP C have provided useful information (McMahon et al., 2001; Turnbull et al., 2003; Zeng et al., 2003) , reinforcing the biological relevance of our model. It is intriguing that depletion of iron from infectious brain homogenates reduces PK-resistant PrP
Sc 5-to 10-fold without altering ferritin levels. One plausible explanation for this result could be that the interaction of PrP Sc and ferritin is mediated through iron, and the inherently PK-resistant nature of ferritin confers stability to associated PrP Sc (Mishra et al., 2004) . We have observed relatively higher resistance of brain-derived ferritin to PK digestion compared with cellular ferritin, a fact that may explain the comparably higher PK resistance of brain PrP Sc (100 g/ml) compared with cell-associated PrP Sc (15 g/ ml). Whether reduction of PK-resistant PrP Sc by iron depletion will decrease infectivity of sCJD and mouse scrapie brain homogenates and ScN2a cells is unclear from our data, but copper chelation has been shown to delay disease onset in experimental mice (Sigurdsson et al., 2003) , providing optimism for iron chelation as a possible means for decreasing PrP Sc load. Previous studies have unraveled important facts about the mechanism of PrP Sc generation and propagation. For example, nonfibrillar PrP Sc particles containing 14 -28 molecules seem to be sufficient for efficient transmission of prion infectivity, although cell-specific factors are necessary for successful PrP Sc propagation (Vorberg et al., 2004; Magalhaes et al., 2005; Bieschke et al., 2004) . Conversion of cellular, brain-derived, or recombinant PrP C to a PrP Sc -like form has been achieved in vitro by incubation with brainderived infectious PrP Sc , RNA molecules, redox-active metals such as copper, certain denaturants, solvents, pH and temperature conditions, reducing agents, inhibition of glycosylation, by the protein misfolding cyclic amplification reaction, and a combination of buffer conditions and metal ions (Brown et al., (Notably, cells exposed to DFO looked healthier than untreated controls after 24 h.) Subsequently, cells were washed with PBS, and lysates were treated with vehicle or 7.5 and 15 g/ml PK for 5 min at 37°C. Resistant proteins were recovered and immunoblotted with 8H4. Control sample without DFO and PK treatment shows the expected glycoforms of PrP (lane 1), some of which are degraded by PK treatment (lanes 2 and 3). Exposure to 5 and 10 M DFO shows a significant decrease in PK-resistant PrP Sc , more so in the latter sample (lanes 4 -9). (B) Reprobing for ferritin shows limited sensitivity to PK regardless of DFO treatment (lanes 1-9). Certain oligomeric forms decrease in intensity (lanes 1-9, solid arrowheads), whereas others increase following PK treatment (lanes 1-9, white arrowhead). (C) Quantification shows a significant decline in PK-resistant PrP
Sc from 99 to 70% and from 70 to 40% with 7.5 and 15 g/ml PK, respectively, after exposure to 5 M DFO. A further decline in PK-resistant PrP Sc to 30 and 18%, respectively, is observed when the DFO concentration is increased to 10 M. n ϭ 4. (D) The total amount of PK-resistant ferritin ranges between 75 and 95% regardless of DFO treatment. n ϭ 4. 2000; Qin et al., 2000; Nishina et al., 2004; Castilla et al., 2005; Kim et al., 2005) . Our report extends these studies by generating a PrP Sc -like molecule in a biologically relevant ex vivo model by using doses of redox iron that are close to the levels detected in prion-infected brains. Moreover, similar doses of FeCl 2 when added to cell lysates do not induce a change in conformation of PrP C to *PrP Sc (our unpublished observations), implicating cellular factors and/or signaling pathways in the process, not a simple chemical or a biophysical reaction. Whether the observed effects are due to redox cycling of metal ions in general, including copper, or they are specific to iron remains to be determined. Although our hypothesis implicating redox iron as a major trigger for PrP Sc propagation answers only some pieces of the prion puzzle, the significance and novelty of the data far exceed its shortcomings and lay the foundation for further investigations on the role of brain iron homeostasis in prion disease pathogenesis, and iron chelation as a potential strategy for reducing PrP Sc load.
